Comparison of Cefuroxim versus Cefotaxim in the Treatment of Pneumonia in Children Aged 3 Months- 5 Years an Imaging and Clinical Examination Evidence: Randomized Controlled Trial

Pneumonia is a common and potentially serious infection that affects children throughout the world. The aim of this study was to compare between cefuroxim and cefotaxim in the treatment of children with pneumonia. All 3 months-5 years old children admitted from 2/1/2012 to 4/31/2012 at Dorrah Hospital in Gaza were included in this study. The clinical outcome, length of hospital stay, and the association of pneumonia incidence to gender and age were compared. Of the 110 children admitted for non-complicated community acquired pneumonia (CAP), sixty patients were treated with cefuroxime and fifty were treated with cefotaxim. Clinical outcome and length of hospital stay is similar between both groups. Interestingly, the pneumonia incidence is higher in younger children and males. In conclusion, both drugs have similar treatment efficacy in terms of clinical outcome and the length of hospital stay. However, cefuroxim has several advantages over cefotaxim, including (1) oral form, allowing outpatient management, (2) less frequency of administration. Thereby, it should be recommended to treat pneumonia in children.

PDF

___

1. Barson WJ, Edwards MS, Mallory GB, Torkya MM. Pneumonia in children: inpatient treatment. http://www.uptodate.com/contents/pneumonia-in-children-inpatienttreatment access date 30.03.2014

2. Jokinen C, Heiskanen L, Juvonen H, Kallinen S, Karkola K, Korppi M, Kurki S, Rönnberg PR, Seppä A, Soimakallio S. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol. 1993;137(9):977-88.

3. Bennett NJ, Joseph Domachowske J, Steele RW. Pediatric Pneumonia. http://emedicine.medscape.com/article/967822-overview access date 30.03.2014

4. Principi N, Esposito S. Mycoplasma pneumoniae and Chlamydia pneumoniae cause lower respiratory tract disease in paediatric patients. Curr Opin Infect Dis. 2002;15(3):295-300.

5. Heiskanen-Kosma T, Korppi M, Jokinen C, Kurki S, Heiskanen L, Juvonen H, Kallinen S, Stén M, Tarkiainen A, Rönnberg PR, Kleemola M, Mäkelä PH, Leinonen M. Etiology of childhood pneumonia: serologic results of a prospective, populationbased study. Pediatr Infect Dis J. 1998;17(11):986-91.

6. Ostapchuk M, Roberts DM, Haddy R. Community-acquired pneumonia in infants and children. Am Fam Physician. 2004;70(5):899-908.

7. Le Saux N, Robinson J. Pneumonia in healthy Canadian children and youth: Practice points for management. Paediatr Child Health. 2011;16(7):417-24.

8. Cincinnati Children's Hospital Medical Center Health Policy and Clinical Effectiveness Program. Evidence based clinical practice guideline. Community acquired pneumonia in children 60 days to 17 years of age. http://www.cincinnatichildrens.org/assets/0/78/1067/2709/2777/2793/9199/1633ae60- cbd1-4fbd-bba4-cb687fbb1d42.pdf access date 30.03.2014

9. Bolton CE, Bevan-Smith EF, Blakey JD, Crowe P, Elkin SL, Garrod R, Greening NJ, Heslop K, Hull JH, Man WD, Morgan MD, Proud D, Roberts CM, Sewell L, Singh SJ, Walker PP, Walmsley S. British Thoracic Society guidelines for the management of community acquired pneumonia in childhood. Thorax. 2013;68(Suppl 2):1-30.

10. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, Kaplan SL, Mace SE, McCracken GH Jr, Moore MR, St Peter SD, Stockwell JA, Swanson JT. The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the pediatric infectious diseases society and the infectious diseases society of America. Clin Infect Dis. 2011;53(7):617-30.

11. Bradley JS. New recommendations for pediatric pneumonia treatment. http://blogs.cdc.gov/safehealthcare/2011/09/30/new-recommendations-for-pediatricpneumonia-treatment access date 30.03.2014

12. Management of community acquired pneumonia in childhood 2002. https://www.britthoracic.org.uk/guidelines-and-quality-standards/community-acquired-pneumonia-inchildren-guideline access date 30.03.2014

13. Finkel R, Clark MA, Cubeddu LX. Lippincott's Illustrated Reviews: Pharmacology, 4th ed. Lippincott, Williams & Wilkins, Philadelphia, 2009.

14. Sader HS, Jacobs MR, Fritsche TR. Review of the spectrum and potencyof orally administered cephalosporins and amoxicillin/ clavulanate. Diagn Microbiol Infect Dis. 2007;57 (Suppl 3):5S-12S.

15. Bradley JS, Garonzik SM, Forrest A, Bhavnani SM. Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose to treat an infection. Pediatric Infect Disease J. 2010;29(11):1043-6.

16. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol. 2004;2(4):289-300.

17. Dimopoulos G, Matthaiou DK,Karageorgopoulos DE, Grammatikos AP, Athanassa Z, Falagas ME. Short- versus long course antibacterial therapy for community acquired pneumonia: a meta-analysis. Drugs. 2008;68(13):1841-54.

18. Amarilyo G, Glatstein M, Alper A, Scolnik D, Lavie M, Schneebaum N, Grisaru-Soen G, Assia A, Ben-Sira L, Reef S. IV Penicillin G is as effective as iv cefuroxime in treating community-acquired pneumonia in children. Am J Ther. 2014;21(2):81-4.

19. Kliegman RM, Stanton BFSt. Geme JW, Schor NF, Behrman RE. Nelson of Textbook of Pediatrics, 19th ed. Elsevier Saunders, USA, 2011.

20. Amin, R, Hoque AMW, Khan RF, Rahman M. Considering respiratory tract infections and antimicrobial sensitivity: An exploratory analysis. Mal. J. Microbiol. 2009;5(2):109-12.

21. Petitpretz P, Chone C, Tremolieres F. Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval. Int J Antimicrob Agents. 2007;30(1):52-9.

22. Dinur-Schejter Y, Cohen-Cymberknoh M, Tenenbaum A, Brooks R, Averbuch D, Kharasch S, Kerem E. Antibiotic treatment of children with community-acquired pneumonia: Comparison of penicillin or ampicillin versus cefuroxime. Pediatr Pulmonol. 2013;48(1):52-8.

23. Olivier C. Clinical use of cefuroxime in paediatric community-acquired pneumonia. Paediatr Drugs. 2000;2(5):331-43.

24. Paladino JA, Gudgel LD, Forrest A, Niederman MS. Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest. 2002;122(4):1271-9.

25. The Union cefuroxime sodium Tanreqing clinical studies in children with bronchial pneumonia treatment. http://eng.hi138.com/medicine-papers/clinical-medicinepapers/201301/434467_the-union-cefuroxime-sodium-tanreqing-clinical-studies-inchildren-with-bronchial-pneumonia-treatment.asp#.U0_Q5vl_t64 access date 30.03.2014

26. Sader HS, Jacobs MR, Fritsche TR. Review of the spectrum and potencyof orally administered cephalosporins and amoxicillin/ clavulanate. Diagn Microbiol Infect Dis. 2007;57:5S-12S.

27. Chen X, Chen C, Chen Y. Reduning cefuroxime curoxime sodium for treatment of joint community-acquired pneumonia in children area 120 cases of clinical observation. J Chengdu Med College. 2009;4(2):117-9.